Streetbeat News

Products Services

AKBA

Akebia Therapeutics' stock price increased following the FDA's approval of Vafseo tablets, a treatment for anemia caused by chronic kidney disease in adults on dialysis.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:24 am

ALIT

Alight has announced the first major release of Alight Worklife for 2024, marking a significant development in their product offerings.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:23 am

LASE

Laser Photonics has emphasized the significance of its Cleantech Laser Systems in the motorcycle repair and restoration industry, showcasing the technology's application in this niche market.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:21 am

MIST

Milestone Pharmaceuticals announced the resubmission of its New Drug Application (NDA) for Etripamil, aimed at treating Paroxysmal Supraventricular Tachycardia (PSVT). This step marks a significant progress in the drug's journey towards market approval.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:17 am

MRK

On Wednesday, U.S. stock markets closed higher, with the Dow and S&P 500 seeing significant gains, partly led by Merck (NYSE:MRK) ahead of inflation data and Fed insights. U.S. mortgage applications slightly fell, while crude oil stocks unexpectedly rose. All major S&P sectors gained, with utilities and real estate leading. Global markets showed mixed results, with Japan's Nikkei falling but markets in Australia, India, China, and Europe rising. Commodities saw gold exceeding $2,220, while crude oil and natural gas prices varied.

Portfolio Pulse from Akanksha Bakshi

March 28, 2024 | 11:16 am

ALDX

Aldeyra Therapeutics announced its clinical development plan for the resubmission of a New Drug Application (NDA) for Reproxalap, a treatment for dry eye disease. This step is crucial for advancing the drug towards potential FDA approval and market entry.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:14 am

BGNE

Genfleet Therapeutics has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland to initiate a Phase 1B/2 trial combining GFH009 and Brukinsa (Zanubrutinib) for treating Diffuse Large B Cell Lymphoma.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:14 am

GOGO

Gogo Business Aviation has reached a significant milestone with its Gogo Galileo Global Broadband Service, achieving complete end-to-end connectivity. This development marks a crucial step forward in providing global broadband services to business aviation clients, enhancing their in-flight connectivity experience.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:11 am

RGNX

REGENXBIO Inc. (NASDAQ:RGNX) announced the publication of Phase I/IIa trial results for ABBV-RGX-314, a gene therapy for wet AMD, in The Lancet. The study, showing positive results for safety and tolerability, supports ongoing pivotal trials of this potential one-time treatment.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:09 am

KPRX

Kiora Pharmaceuticals announced it will present additional data from its ABACUS-1 trial of KIO-301 for treating Retinitis Pigmentosa at the ARVO 2024 Annual Meeting. This development could indicate positive progress in KIO-301's clinical trials, potentially impacting Kiora Pharmaceuticals' stock.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 10:51 am